SecBot SecBot
SECBOTREPLAY Home › Report › ASND

ASND · Ascendis Pharma announced that YUVIWEL (navepegritide), its once-weekly…

Ascendis Pharma A/S · 6-K filed Apr 7, 2026 at 06:01 ET

At the news

BULLISHIMPACT 8/10

6-K filed Apr 7, 2026 at 06:01 ET

Ascendis Pharma announced that YUVIWEL (navepegritide), its once-weekly treatment for children with achondroplasia, has been granted orphan drug exclusivity by the FDA and is now commercially available in the United States. The exclusivity extends through February 27, 2033, providing market protection for this first-in-class therapy.

  • YUVIWEL (navepegritide) received orphan drug exclusivity from the FDA
  • YUVIWEL is now commercially available in the U.S.
  • It is the first and only once-weekly treatment approved to increase linear growth in children 2 years and older with achondroplasia
  • Orphan drug exclusivity runs through February 27, 2033

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access